Vir Biotechnology, Inc. (VIR)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Vir Biotechnology, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Vir Biotechnology, Inc. (VIR) has returned 48.59% so far this year and 38.27% over the past 12 months.

Based on dividend-adjusted daily data since Oct 11, 2019, VIR's average daily return is +0.15%, while the average monthly return is +2.27%. At this rate, your investment would double in approximately 2.6 years.

Historically, 46% of months were positive and 54% were negative. The best month was Jan 2021 with a return of +141.0%, while the worst month was Jul 2023 at -42.6%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 5 months.

On a daily basis, VIR closed higher 48% of trading days. The best single day was Jan 26, 2021 with a return of +74.3%, while the worst single day was Jul 20, 2023 at -44.9%.

Vir Biotechnology, Inc. has an annualized alpha of 30.05%, beta of 0.72, and R² of 0.02 versus S&P 500 Index. Calculated based on daily prices since October 14, 2019.

• This stock participated in 91.78% of S&P 500 Index downside but only 25.73% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.02 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

VIR ranks 61 for risk / return — better than 61% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Vir Biotechnology, Inc. (VIR) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Vir Biotechnology, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Vir Biotechnology, Inc. was 94.85%, occurring on Aug 11, 2025. The portfolio has not yet recovered.

The current Vir Biotechnology, Inc. drawdown is 89.21%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Vir Biotechnology, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Vir Biotechnology, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.